Schreiner MediPharm and WuXi XDC Collaborate on Light-Protect Labels for Sensitive Drug Trials

Schreiner MediPharm has partnered with WuXi XDC to create a specialized Light-Protect-Label for use in clinical trials. This innovative label shields light-sensitive drug components while still allowing visibility of the vial’s contents, which ensures correct and safe administration. The product combines light protection with a blinding function, preventing any bias during trials.

This new label solution enhances the efficiency of clinical trials for antibody drug conjugates (ADCs), which are crucial in targeted cancer therapies. By safeguarding the integrity of sensitive drugs, it contributes to safer, more effective treatments.

Through this collaboration, Schreiner MediPharm is helping advance the development of ADCs, which offer targeted cancer treatment with fewer side effects. The innovative label plays a critical role in preserving these delicate drugs, facilitating smoother clinical trials and ensuring better patient outcomes.